Risk factors of doxorubicin-induced cardiomyopathy in non-muscle- invasive bladder cancer
Article Sidebar
Main Article Content
Abstract
Background
Doxorubicin is an anthracycline antibiotic widely used as a chemotherapeutic agent to treat solid tumors and hematologic malignancies. Bladder cancer is the second most common genitourinary malignancy and can be classified into muscle-invasive bladder cancer and non-muscle-invasive bladder cancer (NMIBC). In Indonesia, NMIBC is treated by doxorubicin instillation. Several risk factors have been suggested to be associated with doxorubicin-induced cardiomyopathy, but on their quantitative effects no consensus has as yet been reached. This study aimed to determine the risk factors of doxorubicin-induced cardiomyopathy in NMIBC patients with intravesical doxorubicin instillation.
Methods
A cross-sectional study was conducted involving 74 NMIBC patients who received local treatment by doxorubicin instillation after transurethral resection of bladder tumor (TURBT). Data were collected on the risk factors that may be favorable to doxorubicin-induced cardiomyopathy, namely age, sex, hypertension, type 2 diabetes mellitus, smoking, and NMIBC risk classification. The dependent variable was cardiomyopathy with decreasing left ventricular ejection fraction (LVEF) below 50 %. Multiple logistic regression was used to analyze the data.
Results
The prevalence of cardiomyopathy was 6.75% (5/74). Type 2 diabetes mellitus was a significant risk factor for doxorubicin-induced cardiomyopathy among our subjects (aOR=34.30;95% C.I.:1.36-865-86;p=0.032). In contrast, age, sex, risk classification, hypertension, and smoking were nonsignificant predictors for doxorubicin-induced cardiomyopathy (p>0.05).
Conclusion
This study demonstrated that type 2 diabetes mellitus increased the risk of cardiomyopathy in doxorubicin users among patients with NMIBC. More research is necessary regarding the mechanisms underlying type 2 diabetes mellitus as a risk factor for doxorubicin-induced cardiomyopathy.
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
How to Cite
References
Leslie SW, Soon-Sutton TL, Aeddula NR. Bladder Cancer. 2024 Aug 15. In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2024.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108. https://doi.org/10.3322/caac.21262.
Umbas R, Safriadi F, Mochtar CA, Djatisoesanto W, Hamid ARAH. Urologic cancer in Indonesia. Jpn J Clin Oncol 2015;45:708–12. https://doi.org/10.1093/jjco/hyv066.
Gontero P, Compérat E, Dominguez-Escrig JL, et al. EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). European Association of Urology;2023.
Goldberg IP, Lichtbroun B, Singer EA, Ghodoussipour S. Pharmacologic therapies for non-muscle invasive bladder cancer: current and future treatments. Arch Pharmacol Ther 2022;4:13-22.
Jin X, Zhang P, Luo L, et al. Efficient intravesical therapy of bladder cancer with cationic doxorubicin nanoassemblies. Int J Nanomedicine 2016;11:4535–44. https://doi.org/10.2147/IJN.S103994.
Belger C, Abrahams C, Imamdin A, Lecour S. Doxorubicin-induced cardiotoxicity and risk factors. IJC Heart Vasculature 2024;50:101332. https://doi.org/10.1016/j.ijcha.2023.101332.
Murabito A, Hirsch E, Ghigo A. Mechanisms of anthracycline-induced cardiotoxicity: Is mitochondrial dysfunction the answer? Front Cardiovasc Med 2020;7:35. https://doi.org/10.3389/fcvm.2020.00035.
Becker MMC, Arruda GFA, Berenguer DRF, Buril RO, Cardinale D, Brandão SCS. Anthracycline cardiotoxicity: current methods of diagnosis and possible role of 18F-FDG PET/CT as a new biomarker. Cardio-Oncology 2023;9:17. https://doi.org/10.1186/s40959-023-00161-6.
Qiu S, Zhou T, Qiu B, et al. Risk factors for anthracycline-induced cardiotoxicity. Front Cardiovasc Med 2021;8:736854. doi: 10.3389/fcvm.2021.736854.
Al Balushi J, Valko SP, Nwosu M, et al. Understanding cardiomyopathy induced by doxorubicin therapy: mechanisms, diagnosis, and management strategies. J Cardiol Cardiovasc Ther 2024;19:556012. DOI: 10.19080/JOCCT.2024.19.556012.
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al.; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37:2768-801. doi: 10.1093/eurheartj/ehw211. Erratum in: Eur Heart J 2018;39:839. doi: 10.1093/eurheartj/ehw562 n.d.
Kim YA, Cho H, Lee N, et al. Doxorubicin‐induced heart failure in cancer patients: a cohort study based on the Korean National Health Insurance Database. Cancer Med 2018;7:6084–92. https://doi.org/10.1002/cam4.1886.
Trasca L, Popescu MR, Popescu AC, Balanescu SM. Echocardiography in the diagnosis of cardiomyopathies: current status and future directions. Rev Cardiovasc Med 2022;23:280. https://doi.org/10.31083/j.rcm2308280.
Jin X, Zhang P, Luo L, et al. Efficient intravesical therapy of bladder cancer with cationic doxorubicin nanoassemblies. Int J Nanomedicine 2016;11:4535–44. https://doi.org/10.2147/IJN.S103994.
Seo GH, Kim JH, Ku JH. Clinical practice pattern of immediate intravesical chemotherapy following transurethral resection of a bladder tumor in Korea: National Health Insurance Database Study. Sci Rep 2016;6:22716. https://doi.org/10.1038/srep22716.
Alrabadi A, Abuhamad M, Mansi H, et al. Delayed bladder perforation related to immediate single dose intravesical doxorubicin instillation after TURBT: a case report and literature review. Clin Med Insights Case Rep 2021;14:1179547620986158. https://doi.org/10.1177/1179547620986158.
Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother 2021;139:111708. doi: 10.1016/j.biopha.2021.111708.
Dulf PL, Mocan M, Coadă CA, et al. Doxorubicin-induced acute cardiotoxicity is associated with increased oxidative stress, autophagy, and inflammation in a murine model. Naunyn Schmiedebergs Arch Pharmacol 2023;396:1105–15. https://doi.org/10.1007/s00210-023-02382-z.
Akbar M, Maulana A, Widagdo Arifin S, Hairul Umam M. Cardiotoxicity caused by intravesical doxorubicin (DOX) after TURBT: a case report. Lombok J Urol 2022;1:106-11.
Lam CSP, Yancy C. Universal definition and classification of heart failure: is it universal? Does it define heart failure? J Card Fail 2021;27:509-11. doi: 10.1016/j.cardfail.2021.03.003.
Mathew T, Williams L, Navaratnam G, et al. Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography. Echo Res Pract 2017;4:G1–13. doi: 10.1530/ERP-16-0037.
Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: An update of mechanisms contributing to this clinical entity. Circ Res 2018;122:624–38. https://doi.org/10.1161/CIRCRESAHA.117.311586.